The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

Clinical trial NCT07126782 · RECRUITING

Trial details

NCT number: NCT07126782
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

AML (Acute Myelogenous Leukemia)AML

Start date: 2025-07-20
Primary completion: 2027-12-20
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.